Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.

[1]  L. Mansfield,et al.  Effects of fexofenadine, diphenhydramine, and placebo on performance of the test of variables of attention (TOVA). , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  R. Townley,et al.  Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma , 2002, European Respiratory Journal.

[3]  M. Bende,et al.  A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  T. Casale,et al.  Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.

[5]  J. Bousquet,et al.  Allergic rhinitis and its impact on asthma. , 2001, The Journal of allergy and clinical immunology.

[6]  H. Milgrom,et al.  Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). , 2001, Pediatrics.

[7]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[8]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[9]  David Skoner,et al.  Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. , 2001, The Journal of allergy and clinical immunology.

[10]  L. Trupin,et al.  The work impact of asthma and rhinitis: findings from a population-based survey. , 2001, Journal of clinical epidemiology.

[11]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[12]  G. Scadding,et al.  Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. , 2000, Clinical otolaryngology and allied sciences.

[13]  S. Spector,et al.  Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  E. Juniper.  Impact of upper respiratory allergic diseases on quality of life. , 1998, The Journal of allergy and clinical immunology.

[15]  E. Juniper.  Quality of life in adults and children with asthma and rhinitis , 1997, Allergy.

[16]  G. Guyatt,et al.  Interpretation of rhinoconjunctivitis quality of life questionnaire data. , 1996, The Journal of allergy and clinical immunology.

[17]  Simons Fe.  Learning impairment and allergic rhinitis. , 1996 .

[18]  Davies Rj,et al.  The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. , 1993 .

[19]  G. Guyatt,et al.  Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire. , 1993, Annals of allergy.

[20]  A. Valero,et al.  Treatment of perennial allergic rhinitis with cetirizine. , 1992, Allergologia et immunopathologia.

[21]  D. Tinkelman,et al.  Clinical evaluation of triamcinolone acetonide nasal aerosol in children with perennial allergic rhinitis. , 1991, Annals of allergy.

[22]  G. Guyatt,et al.  Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[23]  S. Sullivan,et al.  The health economics of asthma and rhinitis. I. Assessing the economic impact. , 2001, The Journal of allergy and clinical immunology.

[24]  G. D. Cioppa,et al.  Erratum: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics (European Respiratory Journal (2001) vol. 18 (254-261)) , 2001 .